meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cometinib
nivolumab based treatment
nivolumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs anti-PD-(L)1
vs pembrolizumab based treatment
vs pembrolizumab alone
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (brain) NO
metastasis (brain) YES
metastasis (liver )
PDL1 (TC0 and IC0 : <1% of TC and IC)
PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC)
stage III (locally advanced)
stage IV (metastatic)
stage M0/M1A/M1B
stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
Abdominal pain AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Constipation AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Dermatitis acneiform AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Increased Lipase Level AE (grade 3-4)
Nausea AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Rash maculopapular AE (grade 3-4)
Sepsis AE (grade 3-4)
Vomiting AE (grade 3-4)
DCR
mML - L1 - BRAF wild
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - BRAF wild
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone
1
certainty unassessable
-8%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open